Clinical trial
Standard Dose Versus Myeloablative Therapy for Previously Untreated Symptomatic Multiple Myeloma, A Phase III Intergroup Study
NCT00002548 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Standard Dose Versus Myeloablative Therapy for Previously Untreated Symptomatic Multiple Myeloma, A Phase III Intergroup Study
- Lead sponsor
- SWOG Cancer Research Network
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 1994
- Completion date
- November 30, 2006
- Enrollment
- 899 (actual)
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.